Business Context and Reporting Period
Lexaria Bioscience Corp. filed this Form 8-K on April 3, 2017, to report the completion of a brokered private placement of equity securities. The company is incorporated in Nevada with principal executive offices in Kelowna, BC, Canada.
Key Financial Metrics
- Gross Proceeds: US$1,723,798
- Units Issued: 4,104,280
- Offering Price: US$0.42 per Unit
- Unit Composition: One common share and one-half of one share purchase warrant.
- Warrant Terms: Exercise price of US$0.60 per share; 24-month term.
- Agent Compensation: 7% cash commission of gross proceeds plus 287,300 compensation units (exercisable at US$0.42 with warrants at US$0.60).
Material Changes
This filing represents a discrete capital raise event rather than a periodic financial performance report. Consequently, there are no comparative revenue, profit, or margin changes versus a prior period disclosed in this document. The primary material change is the increase in outstanding share count and the injection of capital.
Use of Proceeds and Outlook
Management intends to utilize the net proceeds for the following purposes:
- Funding a research collaboration with the National Research Council Canada.
- Advancing R&D related to the delivery and bioavailability of cannabis, vitamins, NSAIDs, and nicotine.
- Working capital and general corporate purposes.
Risks and Contingencies: The securities were issued in an offshore transaction to non-U.S. persons pursuant to Regulation S. They are subject to a four-month and one-day hold period in Canada and have not been registered under the U.S. Securities Act of 1933.
Investor Verification Checklist
- Verify the exact number of shares and warrants outstanding post-closing.
- Confirm the specific terms of the research collaboration with the National Research Council Canada.
- Review the company's cash burn rate to assess the runway provided by the US$1.72 million in gross proceeds.
- Check for any subsequent filings regarding the registration of these securities for U.S. trading.